Arstat Pharmaceuticals is a leading pharmaceutical company that is focused on developing novel medical devices and products that cater to women’s health. The company’s high-value portfolio comprises products that have proven efficacy and safety, specifically designed to address major areas of unmet medical needs in women’s health.
Nuvocept: The First Oral Contraceptive for Overweight and Obese Women
Arstat’s most valuable asset, Nuvocept, is the first and only oral contraceptive designed explicitly for overweight and obese women. The product has already gained the FDA’s endorsement for its unprecedented clinical program and potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the U.S. contraceptive market, catering to the needs of approximately 50 million women.
Pipeline and Market Potential
Arstat Pharmaceuticals’ pipeline comprises four drug candidates, of which two are phase III-ready, and two others are ready for phase IIb. The addressable US market for Arstat’s products is approximately 50 million women, with projected peak US net sales of $3.0 – 4.0 billion. The targeted global market may exceed 800 million women with significant European and worldwide sales.
Founder and CEO’s Expertise
The Founder and CEO of Arstat Pharmaceuticals, Arkady Rubin, has over 30 years of industry experience, having worked with top pharmaceutical companies such as J&J and Pfizer. He is the co-inventor of Ortho Tri-Cyclen Lo, the best-selling oral contraceptive in the U.S. with peak sales exceeding $500 million per year. With his extensive knowledge and expertise in the field, Rubin has been instrumental in leading Arstat Pharmaceuticals towards success.
Fundraising and Growth
Arstat is currently raising a seed financing round to hire key executives, assemble a top-notch Board of Directors, and gear up for a $50.0 million public offering in the coming year. The company plans to use the proceeds raised in the public offering to advance its Phase III candidates through NDA filing, FDA approval, and sale or out-licensing within 3 – 3.5 years from the initial financing round. Conservative estimates of the fair value of Arstat’s product portfolio at the time of the public offering are between $500 – $800 million, indicating a promising growth trajectory for the company.
Arstat Pharmaceuticals is at the forefront of innovative women’s healthcare, developing products that cater to major unmet medical needs. With its robust pipeline and market potential, Arstat is poised to make a significant impact in the healthcare industry, catering to the needs of millions of women worldwide.
Ready to amplify your reach and engage with the most dynamic community in the venture world? Consider sponsoring an article with us. Learn more about our promotional opportunities and sponsored articles here.
Your story could be the next big hit on US Venture News!